Spondyloarthritis & psoriatic arthritis
Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis
Authors' conclusion
Early, treatment-naïve PsA patients exhibit a distinct pro-atherogenic lipid profile, characterised by decreased ApoA1 and increased ApoB levels, distinguishing them from early RA patients and healthy controls.
Study context
- Population
- Newly diagnosed, treatment-naïve psoriatic arthritis (PsA) patients, with sex- and age-matched healthy controls and early untreated rheumatoid arthritis (RA) patients
- Participants
- 75 / 61 / 50
- Exposure
- Early untreated PsA vs healthy controls and early untreated RA
- PsAn = 75
- Healthy control (HC)n = 61reference
- RAn = 50
- Outcome
- Serum lipid profile: total cholesterol, non-HDL-c, low-density lipoprotein cholesterol (LDL-c), HDL-c, triglycerides, apolipoprotein B (ApoB) and ApoA1
Methodological detailssex- and age-matched controls
- Sex- and age-matched controls
Main finding
As reported in the abstract
Serum lipids and apolipoproteins across PsA, RA and HC
- PsA vs HC: P = 0.006
- PsA vs HC: P < 0.001
- PsA vs HC: P < 0.001
Observational data: associations, not effects.
Further findings
- Apolipoprotein A1 (ApoA1) as predictor of PsA diagnosis
- 90.6% · accuracy (regression, adjusted) · specificity 82.4% · sensitivity 83.8% · optimal cut-off 1403 µg/mL · AUC (95% CI) 0.886 (0.83 to 0.941)
Original publication
Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis. RMD Open. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →